1. 首页
  2. 产品
  3. Signaling Pathways 信号通路
  4. Others | 其他产品
  5. Others 12

Glatiramer acetate

别名: 醋酸格拉替雷;L-丙氨酸-L-谷氨酸-L-赖氨酸-L-酪氨酸多肽聚合物醋酸盐; 格拉默-D7; 格拉替雷; 格拉替美; 醋酸格卡替雷;格拉替雷-D7
目录号: V64328 纯度: ≥98%
COA 产品数据 产品说明书 SDS
醋酸格拉替雷是髓磷脂碱性蛋白的合成类似物，也是一种可用于多发性硬化症研究的免疫调节剂。
Glatiramer acetate CAS号: 147245-92-9
产品类别: Others 12
产品仅用于科学研究，不针对患者销售
规格 价格 库存 数量
1mg
5mg
10mg
50mg
100mg
Other Sizes
加入购物车 结帐 大包装询价
020-31522723 sales@invivochem.cn
点击了解更多
  • 与全球5000+客户建立关系
  • 覆盖全球主要大学、医院、科研院所、生物/制药公司等
  • 产品被大量CNS顶刊文章引用
InvivoChem产品被CNS等顶刊论文引用
产品描述
醋酸格拉替雷是髓磷脂碱性蛋白的合成类似物，也是一种可用于多发性硬化症研究的免疫调节剂。醋酸格拉默与 MHC 分子表现出强烈且混杂的结合，因此与各种髓磷脂抗原竞争呈递给 T 细胞。醋酸格拉替雷作用的另一个方面是有效诱导 T 辅助细胞 2 (Th2) 特异性抑制细胞迁移到大脑中并导致原位旁观者抑制。
生物活性&实验参考方法
体外研究 (In Vitro)
醋酸戊二酰胺（25–100 mg/kg；Sc；5 天）可提高 BDNF 水平[3]。用于亨廷顿病 (HD) 动物模型的 N171-82Q 转基因小鼠系显示出更快的病程。从8周龄开始一直持续到20周龄（接近该疾病导致死亡的年龄），小鼠给予1毫克/只； SC； 5×周。多项运动功能评估显示，使用醋酸戊二醛可改善运动功能。对 15 周大的 N171-82Q 转基因小鼠进行为期 4 天的转棒测试，结果显示，给予醋酸戊二酰胺后，小鼠的表现有显着改善[3]。
参考文献
[1]. McKeage K. Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review. CNS Drugs. 2015;29(5):425-432.
[2]. Arnon R, et al. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A. 2004;101 Suppl 2(Suppl 2):14593-14598.
[3]. Corey-Bloom J, et al. Beneficial effects of glatiramer acetate in Huntington's disease mouse models: Evidence for BDNF-elevating and immunomodulatory mechanisms. Brain Res. 2017;1673:102-110.
[4]. Aharoni R, et al. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ [published correction appears in Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12288]. Proc Natl Acad Sci U S A
其他信息
一种由L-丙氨酸、L-谷氨酸、L-赖氨酸和L-酪氨酸组成的随机聚合物，其结构与髓鞘碱性蛋白相似。它用于治疗复发缓解型多发性硬化症。
另见：醋酸格拉替雷（注释已移至）。
*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性
化学信息 & 存储运输条件
分子式
(C9H11NO3.C6H14N2O2.C5H9NO4.C3H7NO2)X.XC2H4O2
分子量
623.65
精确质量
623.301
CAS号
147245-92-9
PubChem CID
3081884
外观&性状
Off-white to light yellow solid powder
沸点
385.2ºC at 760mmHg
熔点
>239°C (dec.) (lit.)
闪点
186.7ºC
蒸汽压
1.27E-06mmHg at 25°C
LogP
2.147
tPSA
374.13
氢键供体(HBD)数目
12
氢键受体(HBA)数目
18
可旋转键数目(RBC)
13
重原子数目
43
分子复杂度/Complexity
519
定义原子立体中心数目
4
SMILES
CC(=O)O.NCCCCC(C(=O)O)N.OC(CCC(C(=O)O)N)=O.CC(C(=O)O)N.OC(C(CC1=CC=C(O)C=C1)N)=O
InChi Key
FHEAIOHRHQGZPC-KIWGSFCNSA-N
InChi Code
InChI=1S/C9H11NO3.C6H14N2O2.C5H9NO4.C3H7NO2.C2H4O2/c10-8(9(12)13)5-6-1-3-7(11)4-2-6;7-4-2-1-3-5(8)6(9)10;6-3(5(9)10)1-2-4(7)8;1-2(4)3(5)6;1-2(3)4/h1-4,8,11H,5,10H2,(H,12,13);5H,1-4,7-8H2,(H,9,10);3H,1-2,6H2,(H,7,8)(H,9,10);2H,4H2,1H3,(H,5,6);1H3,(H,3,4)/t8-;5-;3-;2-;/m0000./s1
化学名
acetic acid;(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2S)-2-aminopentanedioic acid;(2S)-2-aminopropanoic acid;(2S)-2,6-diaminohexanoic acid
HS Tariff Code
2934.99.9001
存储方式

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

注意： 请将本产品存放在密封且受保护的环境中，避免吸湿/受潮。
运输条件
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
溶解度数据
溶解度 (体外实验)
H2O: 50 mg/mL
溶解度 (体内实验)
注意: 如下所列的是一些常用的体内动物实验溶解配方，主要用于溶解难溶或不溶于水的产品（水溶度<1 mg/mL）。 建议您先取少量样品进行尝试，如该配方可行，再根据实验需求增加样品量。
注射用配方
(IP/IV/IM/SC等)
注射用配方1: DMSO : Tween 80： Saline = 10 : 5 : 85 (如： 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)
*生理盐水/Saline的制备：将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中，得到澄清溶液。
注射用配方 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)
注射用配方 3: DMSO : Corn oil = 10 : 90 (如： 100 μL DMSO → 900 μL Corn oil)
示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液，加到 900 μL Corn oil/玉米油中, 混合均匀。
View More

注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如：100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)]
*20% SBE-β-CD in Saline的制备（4°C，储存1周）：将2g SBE-β-CD (磺丁基-β-环糊精) 溶解于10mL生理盐水中，得到澄清溶液。
注射用配方 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (如： 500 μL 2-Hydroxypropyl-β-cyclodextrin (羟丙基环胡精)→ 500 μL Saline)
注射用配方 6: DMSO : PEG300 : Castor oil : Saline = 5 : 10 : 20 : 65 (如： 50 μL DMSO → 100 μL PEG300 → 200 μL Castor oil → 650 μL Saline)
注射用配方 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (如： 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
注射用配方 8: 溶解于Cremophor/Ethanol (50 : 50), 然后用生理盐水稀释。
注射用配方 9: EtOH : Corn oil = 10 : 90 (如： 100 μL EtOH → 900 μL Corn oil)
注射用配方 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL EtOH → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)

口服配方
口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠)
口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素)
示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中，得到0.5%CMC-Na澄清溶液；然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中，得到悬浮液。
View More

口服配方 3: 溶解于 PEG400 (聚乙二醇400)
口服配方 4: 悬浮于0.2% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 5: 溶解于0.25% Tween 80 and 0.5% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 6: 做成粉末与食物混合

注意: 以上为较为常见方法，仅供参考， InvivoChem并未独立验证这些配方的准确性。具体溶剂的选择首先应参照文献已报道溶解方法、配方或剂型，对于某些尚未有文献报道溶解方法的化合物，需通过前期实验来确定（建议先取少量样品进行尝试），包括产品的溶解情况、梯度设置、动物的耐受性等。
请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。
制备储备液 1 mg 5 mg 10 mg
1 mM 1.6035 mL 8.0173 mL 16.0346 mL
5 mM 0.3207 mL 1.6035 mL 3.2069 mL
10 mM 0.1603 mL 0.8017 mL 1.6035 mL

1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;

3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;

4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。

计算器
计算 重置

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度，具体如下：

  • 计算制备已知体积和浓度的溶液所需的化合物的质量
  • 计算将已知质量的化合物溶解到所需浓度所需的溶液体积
  • 计算特定体积中已知质量的化合物产生的溶液的浓度
使用摩尔浓度计算器计算摩尔浓度的示例如下所示：
假如化合物的分子量为350.26 g/mol，在5mL DMSO中制备10mM储备液所需的化合物的质量是多少？
  • 在分子量（MW）框中输入350.26
  • 在“浓度”框中输入10，然后选择正确的单位（mM）
  • 在“体积”框中输入5，然后选择正确的单位（mL）
  • 单击“计算”按钮
  • 答案17.513 mg出现在“质量”框中。以类似的方式，您可以计算体积和浓度。
计算 重置

稀释计算器可计算如何稀释已知浓度的储备液。例如，可以输入C1、C2和V2来计算V1，具体如下：

制备25毫升25μM溶液需要多少体积的10 mM储备溶液？
使用方程式C1V1=C2V2，其中C1=10mM，C2=25μM，V2=25 ml，V1未知：
  • 在C1框中输入10，然后选择正确的单位（mM）
  • 在C2框中输入25，然后选择正确的单位（μM）
  • 在V2框中输入25，然后选择正确的单位（mL）
  • 单击“计算”按钮
  • 答案62.5μL（0.1 ml）出现在V1框中
g/mol
计算 重置

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成，具体如下：

注：化学分子式大小写敏感：C12H18N3O4  c12h18n3o4
计算化合物摩尔质量（分子量）的说明：
  • 要计算化合物的分子量 (摩尔质量)，请输入化学/分子式，然后单击“计算”按钮。
分子质量、分子量、摩尔质量和摩尔量的定义：
  • 分子质量（或分子量）是一种物质的一个分子的质量，用统一的原子质量单位（u）表示。（1u等于碳-12中一个原子质量的1/12）
  • 摩尔质量（摩尔重量）是一摩尔物质的质量，以g/mol表示。
/
计算 重置

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

  • 输入试剂的质量、所需的配液浓度以及正确的单位
  • 单击“计算”按钮
  • 答案显示在体积框中
动物体内实验配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
第二步：请输入动物体内配方组成（配方适用于不溶/难溶于水的化合物），不同的产品和批次配方组成不同，如对配方有疑问，可先联系我们提供正确的体内实验配方。此外，请注意这只是一个配方计算器，而不是特定产品的确切配方。
+
+
+
计算 重置

计算结果:

工作液浓度： mg/mL；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH2O，混匀澄清。

(1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
            (2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息
Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) 'Prevention of Relapse of Multiple Sclerosis'
CTID: NCT03209479
Phase:    Status: Completed
Date: 2024-06-13
A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate
CTID: NCT05688436
Phase:    Status: Recruiting
Date: 2023-10-13
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
CTID: NCT03368664
Phase: Phase 3    Status: Active, not recruiting
Date: 2023-09-21
Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)
CTID: NCT04079088
Phase: Phase 2    Status: Withdrawn
Date: 2023-06-01
Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)
CTID: NCT00326625
Phase: Phase 2    Status: Completed
Date: 2022-08-03
View More

A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
CTID: NCT01067521
Phase: Phase 3    Status: Completed
Date: 2021-12-09

Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran
CTID: NCT04928313
Phase:    Status: Completed
Date: 2021-06-16
Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness
CTID: NCT00203021
Phase: Phase 4    Status: Completed
Date: 2020-02-18
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
CTID: NCT01633112
Phase: Phase 3    Status: Terminated
Date: 2019-05-28
Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients
CTID: NCT03315923
Phase: Phase 2/Phase 3    Status: Completed
Date: 2019-05-23
Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)
CTID: NCT02153723
Phase: Phase 2    Status: Completed
Date: 2018-11-05
Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate
CTID: NCT01569451
Phase: Phase 2    Status: Completed
Date: 2018-06-08
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)
CTID: NCT00856635
Phase: Phase 3    Status: Completed
Date: 2018-02-06
Safety of New Formulation of Glatiramer Acetate
CTID: NCT00947752
Phase: Phase 3    Status: Completed
Date: 2017-03-14
A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®
CTID: NCT00239993
Phase: Phase 4    Status: Completed
Date: 2017-02-06
Efficacy and Safety of GTR in Comparison to Copaxone®
CTID: NCT01489254
Phase: Phase 3    Status: Completed
Date: 2016-12-29
Treatment of Multiple Sclerosis With Copaxone and Albuterol
CTID: NCT00039988
Phase: N/A    Status: Completed
Date: 2016-09-22
Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
CTID: NCT00451451
Phase: Phase 3    Status: Completed
Date: 2015-01-26
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
CTID: NCT01058005
Phase: Phase 3    Status: Terminated
Date: 2014-09-03
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
CTID: NCT01534182
Phase: Phase 4    Status: Completed
Date: 2014-08-08
Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx
CTID: NCT00211887
Phase: Phase 3    Status: Completed
Date: 2014-04-03
An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
CTID: NCT01578785
Phase: Phase 3    Status: Terminated
Date: 2014-04-02
An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome
CTID: NCT02023424
Phase: Phase 1    Status: Unknown status
Date: 2014-02-04
Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate
CTID: NCT00203047
Phase: Phase 4    Status: Terminated
Date: 2014-01-06
Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
CTID: NCT01167426
Phase: Phase 3    Status: Completed
Date: 2013-10-17
Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis
CTID: NCT00819195
Phase:    Status: Completed
Date: 2013-10-08
Treatment Interruption of Natalizumab
CTID: NCT01071083
Phase: Phase 2    Status: Completed
Date: 2013-09-19
Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis
CTID: NCT00811395
Phase: Phase 2    Status: Completed
Date: 2012-12-31
Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis
CTID: NCT00475865
Phase: Phase 2    Status: Completed
Date: 2012-11-06
Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome
CTID: NCT00666224
Phase: Phase 3    Status: Completed
Date: 2012-06-25
Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).
CTID: NCT00337779
Phase: Phase 3    Status: Completed
Date: 2011-10-10
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.
CTID: NCT00203073
Phase: Phase 2    Status: Completed
Date: 2011-04-14
Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS
CTID: NCT00202995
Phase: Phase 4    Status: Terminated
Date: 2010-10-18
Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)
CTID: NCT00910598
Phase: Phase 4    Status: Unknown status
Date: 2010-02-10
A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose
CTID: NCT00202982
Phase: Phase 2    Status: Completed
Date: 2010-01-14
FOCUS Fatigue Outcome in Copaxone USers
CTID: NCT00267319
Phase: Phase 4    Status: Completed
Date: 2009-12-07
A Double Blind Placebo Control Study to Assess the Safety,Tolerability and Efficacy of Copaxone in Crohn's Disease
CTID: NCT00731172
Phase: Phase 2    Status: Unknown status
Date: 2009-03-03
Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation
CTID: NCT00677664
Phase: Phase 4    Status: Unknown status
Date: 2008-05-14
An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis
CTID: NCT00398528
Phase:    Status: Terminated
Date: 2007-12-05
Gait Evaluation in Multiple Scl
MultipleMS – Multiple-omics approach to accelerate personalised medicine in a prospective cohort of newly diagnosed MS and CIS patients.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2017-09-29
COMBAT-MS (COMparison Between All immunoTherapies for Multiple Sclerosis)
CTID: null
Phase: Phase 4    Status: Completed
Date: 2017-05-22
A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Treated with Subcutaneous Injections of Copaxone® (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily (CONFIDENCE)
CTID: null
Phase: Phase 4    Status: Completed
Date: 2016-01-04
Effects of fingolimod on functional brain adaptation and clinical measures in multiple sclerosis
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2014-12-17
Does targeting of S1P receptors reduce microglial activation in multiple sclerosis?
CTID: null
Phase: Phase 4    Status: Completed
Date: 2013-12-20
A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study To Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copaxone in Patients with Relapsing Remitting Multiple Sclerosis
CTID: null
Phase: Phase 2    Status: Completed
Date: 2013-12-18
Active-controlled phase IIIb study to investigate the ability of the HAP score to predict responders to Octagam 5% in patients with early relapsing multiple sclerosis.
CTID: null
Phase: Phase 3    Status: Completed, Prematurely Ended
Date: 2013-07-05
A 3-year, multi-center study to evaluate optical coherence tomography as an outcome measure in patients with multiple sclerosis
CTID: null
Phase: Phase 3    Status: Completed
Date: 2012-09-19
A multinational, multicenter, randomized, parallel group, double blind, placebo controlled study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml new formulation administered daily by subcutaneous (SC) injection.
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2012-05-15
Multi-centre, randomized, double-blind, placebo-controlled, parallel-group, 9 month, equivalence trial comparing the efficacy and safety and tolerability of GTR (Synthon BV) to Copaxone® (Teva) in subjects with relapsing remitting multiple sclerosis followed by an open-label 15 month GTR treatment part evaluating the long-term GTR treatment effects
CTID: null
Phase: Phase 3    Status: Prematurely Ended, Completed
Date: 2011-09-21
EFFECTS OF GLATIRAMER ACETATE ON TISSUE DAMAGE, CORTICAL FUNCTIONS AND FATIGUE IN MULTIPLE SCLEROSIS: A MORPHO-FUNCTIONAL MRI STUDY.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2011-04-13
A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy
CTID: null
Phase: Phase 3    Status: Completed
Date: 2011-03-15
A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects with Relapsing Remitting Multiple Sclerosis
CTID: null
Phase: Phase 3    Status: Completed, Prematurely Ended
Date: 2010-05-07
Randomized Treatment Interruption of Natalizumab
CTID: null
Phase: Phase 2    Status: Completed
Date: 2010-05-03
A multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of Glatiramer Acetate (GA) injection 40 mg administered three times a week compared to placebo in a double-blind design.
CTID: null
Phase: Phase 3    Status: Completed
Date: 2010-03-30
Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAMUS) - a randomized controlled trial
CTID: null
Phase: Phase 4    Status: Completed
Date: 2010-03-24
The Effect of the Dose of PI-2301 on Efficacy, Safety, and Tolerability, in Subjects with the Relapsing Remitting Form of Multiple Sclerosis:
CTID: null
Phase: Phase 2    Status: Completed, Ongoing, Prematurely Ended
Date: 2009-12-31
A multinational, multicenter, single blood sampling exploratory pharmacogenetic study of the REGARD (the REbif vs Glatiramer Acetate in Relapsing MS Disease) trial
CTID: null
Phase: Phase 4    Status: Completed
Date: 2009-12-18
MITOXANTRONE/GLATIRAMER ACETATE COMBINED TREATMENT IN THE THERAPY OF SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2009-07-30
A Double Blind, Randomised, Placebo Controlled Study Investigating Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis in patients treated with Copaxone for at least 3 months
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2009-03-06
ADVANCED MRI STUDY ON INFLAMMATORY AND DEGENRATIVE DAMAGE IN MULTIPLE SCLEROSIS
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2007-10-30
A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 600mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting (R-R) Multiple Sclerosis (MS).
CTID: null
Phase: Phase 2    Status: Completed
Date: 2007-07-03
A multi-national, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, tolerability and safety of 40 mg glatiramer acetate injection in subjects with amyotrophic lateral sclerosis (ALS)
CTID: null
Phase: Phase 2    Status: Completed
Date: 2006-08-14
A multi-national, multi-centre, randomized, parallel-group, double-blind study to compare the efficacy, tolerability and safety of Glatiramer Acetate Injection 40 mg/ml to that of Glatiramer Acetate Injection 20 mg/ml administered once daily by subcutaneous injection in subjects with relapsing remitting (RR) Multiple Sclerosis (MS)
CTID: null
Phase: Phase 3    Status: Completed, Prematurely Ended
Date: 2006-07-27
A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs. Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2005-07-26
A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 15 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis.
CTID: null
Phase: Phase 2    Status: Completed
Date: 2004-10-22
A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 30 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis.
CTID: null
Phase: Phase 2    Status: Completed
Date: 2004-08-31
A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 300mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting (R-R) Multiple Sclerosis (MS).
CTID: null
Phase: Phase 2    Status: Completed
Date: 2004-07-12

相关产品
  • Lalistat 2
    V64234 1234569-09-5 100mg
    Lalistat 2 is a specific inhibitor of lysosomal acid lipase (LAL) and has no effect on other forms of lipase.
    ¥7500.00
  • D-(-)-3-Phosphoglyceric acid disodium (3-Phospho-D-glyceric acid disodium)
    V73770 80731-10-8 100mg
    D-(-)-3-Phosphoglyceric acid (3-Phospho-D-glyceric acid) disodium is an important intermediate in the enzyme-catalyzed glycolysis process.
    ¥1400.00
  • STC-15
    V75488 2648257-56-9 10mg
    STC-15 (example 70) is an orally bioactive METTL3 inhibitor for the study of proliferative diseases such as cancer and autoimmune diseases.
    ¥7360.00
  • TSR-033
    V75074 2225940-96-3 1mg
    TSR-033 is a high-affinity humanized IgG4 antibody targeting LAG-3 (lymphocyte activation gene-3) that enhances T cell function and PD-1 blocking activity in vitro and in vivo.
    ¥3500.00
联系我们
电话: 020-31522723 传真: 463611831 邮箱: sales@invivochem.cn
获得最新产品资讯、折扣和优惠
姓名
邮箱

InvivoChem的所有产品仅用于作科学研究，不面向患者销售

Copyright 2020 InvivoChem LLC | All Rights Reserved 粤ICP备20063088号-1

 粤公网安备 44011102003439号

联系我们
Home Classify Cart Member